Elosulfase Alfa: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AWMSG (Wales), HAS (France) and PHARMAC (New Zealand) recommended or restricted elosulfase alfa, while NYE METODER (Norway) and SMC (Scotland) did not recommend it.
On the same population the two systems disagree outright: AWMSG (Wales) recorded recommended for “Treatment of mucopolysaccharidosis, type IVA (Morquio A Syndrome, MPS IVA) in patients of all ages”, while SMC (Scotland) recorded not recommended for “treatment of mucopolysaccharidosis, type IVA (Morquio A Syndrome, MPS IVA) in patients of all ages.”.
Assessment has run over 11 years, from 1 Oct 2014 at HAS (France) to 22 Oct 2025 at CIPM (Spain).
CIPM (Spain) changed its position: not recommended on 25 Nov 2021, recommended by 22 Oct 2025, after a resubmission.
No assessment is on file from PBAC (Australia), TLV (Sweden) and G-BA (Germany), each among the eight highest-volume agencies here.
The file is active: 5 of 11 records date from 2023 or later.
HAS (France) was first to assess elosulfase alfa, on 1 Oct 2014; PHARMAC (New Zealand) did not open a file until 11 Aug 2023 — an unusually long tail of 8.8 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 7 years in total.
3 of the 6 agencies here assessed elosulfase alfa more than once, CIPM (Spain) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for elosulfase alfa.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CIPM (Spain) | 16 Jul 2025 | Indicaciones terapéuticas autorizadas: Vimizim® está indicado para el tratamiento de la mucopolisacaridosis, tipo IVA (s… | not financed by the SNS (financed 2025-10) | source |
| PHARMAC (New Zealand) | 11 Aug 2023 | MPS IVA for individuals aged 2 years and over | PTAC advice: Medium | source |
| HAS (France) | 21 Jun 2023 | Re-assessment following post-listing study results | SMR substantial · ASMR IV | source |
| NYE METODER (Norway) | 20 Mar 2022 | Enzymerstatningsterapi ved mukopolysakkaridose type IVA (Morquio A-syndrom, MPS IVA) hos pasienter i alle aldre | not introduced | source |
| AWMSG (Wales) | 16 Mar 2016 | Treatment of mucopolysaccharidosis, type IVA (Morquio A Syndrome, MPS IVA) in patients of all ages | recommended | source |
6 further decisions for elosulfase alfa, across 4 agencies, are not shown here. They include the most recent record on file, 22 Oct 2025 from CIPM (Spain); its outcome is in the subscriber dataset. They link to 5 further source documents.
Related molecules
- teduglutide — same ATC class A16A — Other alimentary tract and metabolism
- sapropterin — same ATC class A16A — Other alimentary tract and metabolism
- miglustat — same ATC class A16A — Other alimentary tract and metabolism
- migalastat — same ATC class A16A — Other alimentary tract and metabolism
- cerliponase alfa — same ATC class A16A — Other alimentary tract and metabolism
- givosiran — same ATC class A16A — Other alimentary tract and metabolism
Coverage: 11 decisions for elosulfase alfa from 6 agencies, 2014 to 2025. Data to 7 Sep 2026. ATC class A16A — Other alimentary tract and metabolism. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.